COMPANY PROFILE

Danma Bio

Explore full profile

Natick, United StatesFounded 2020Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

At a glance

Status: Operational
Founded: 2020
Headquarters: Natick, United States
Employees: 9
Open positions: None listed
Dealroom signal: 23.1/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: LinkedIn

Founder mafia, market maps, research and news connected to this company by Dealroom

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Dec 2022	$20M	$80M	Longpan Investment · Delian Capital	↗

Danma Bio team growth

Danma Bio's team grew 0% over the past year.

1-year team growth0%

Summary metrics are public; monthly history is available with a demoCompare with peers →

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HTHarness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs	Babraham, United Kingdom	Operational	5	$35M	$90M
ZVZiphius VaccinesAddresses urgent global public health needs by developing mRNA-based vaccines	Ghent, Belgium	Operational
KIKimialysDeveloper of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors	Paris, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
BPBrenus PharmaProducing the widest panel of tumor associated antigens and resistance markers with a chemical labeling enable to induce cell death by patients' immune system	Clermont-Ferrand, France	Operational
ABAkston BiosciencesLeverages its core expertise of designing novel fusion proteins to develop and manufacture new classes of biologic therapeutics for Type 1 diabetes (T1D) prevention, ultra-long acting insulin therapy, and vaccines	Beverly, United States	Operational
EBExeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics	Dijon, France	Operational